Alcobra Ltd (ADHD)

1.14
0.00 (0.00)
NASDAQ : Health Care
Prev Close 1.14
Open 1.15
Day Low/High 1.12 / 1.15
52 Wk Low/High 3.15 / 9.50
Volume 142.43K
Avg Volume 863.10K
Exchange NASDAQ
Shares Outstanding 27.56M
Market Cap 31.42M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Alcobra, Ltd. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Alcobra, Ltd. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Alcobra, Ltd., And Encourages Investors To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces An Investigation Of Alcobra, Ltd., And Encourages Investors To Contact The Firm

Khang & Khang LLP (the "Firm") announces that it is investigating claims against Alcobra, Ltd.

SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Alcobra, Ltd. And Encourages Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Alcobra, Ltd. And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Alcobra, Ltd.

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Alcobra, Ltd. And Advises Investors With Losses To Contact The Firm

SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Alcobra, Ltd. And Advises Investors With Losses To Contact The Firm

Goldberg Law PC announces that it is investigating Alcobra Ltd.

Alcobra Shares Plummet as ADHD Drug Fails

Alcobra Shares Plummet as ADHD Drug Fails

Alcobra has plans to restore shareholder value, but it's unclear what that plan will entail.

Alcobra Reports Phase 3 Clinical Trial Of MDX In Adults With ADHD Missed Primary Endpoint

Alcobra Reports Phase 3 Clinical Trial Of MDX In Adults With ADHD Missed Primary Endpoint

Management to hold a conference call & webcast today, January 17th at 8:00 a.m. EST

Alcobra Updates On Recent FDA Meeting

Alcobra Updates On Recent FDA Meeting

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.

Alcobra (ADHD) Stock Sliding, Downgraded After FDA Clinical Hold

Alcobra (ADHD) Stock Sliding, Downgraded After FDA Clinical Hold

Alcobra (ADHD) stock rating was reduced to 'neutral' at Piper Jaffray on Friday.

Alcobra (ADHD) Stock Tumbles on FDA Clinical Hold, Cantor Remains Bullish

Alcobra (ADHD) Stock Tumbles on FDA Clinical Hold, Cantor Remains Bullish

Alcobra (ADHD) announced late yesterday that the FDA has placed a clinical hold on its new drug applications for MDX for ADHD treatment.

Alcobra Announces Second Quarter 2016 Financial Results And Provides Corporate Update

Alcobra Announces Second Quarter 2016 Financial Results And Provides Corporate Update

Conference Call & Webcast August 30th at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time